Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with DC Vaccine, IL-2, and IFN in mRCC
NCT00913913Phase 2Terminated
- Sponsor
- Dartmouth Health
- Start
- Feb 2009
- Primary completion
- Jan 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in metastatic renal cell carcinoma (mRCC), sponsored by Dartmouth Health. Started Feb 2009; status: terminated.
02
Drugs
bevacizumab
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00913913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00913913.